133 Using a scenario approach to assess for the current and future demand of immunoglobulins 89. Perraudin C, Bourdin A, Vicino A, Kuntzer T, Bugnon O, Berger J. Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis. PloS one 2020; 15(11): e0242630. 90. Petrini C. Production of plasma-derived medicinal products: ethical implications for blood donation and donors. Blood transfusion = Trasfusione del sangue 2014; 12 Suppl 1: s389-94. 91. Prevot J, Jolles S. Global immunoglobulin supply: steaming towards the iceberg? Current opinion in allergy and clinical immunology 2020; 20(6): 557-64. 92. Shapiro RS, Boyle M. Payor issues: barriers to optimal management of patients with primary immunodeficiency. Journal of clinical immunology 2012; 32 Suppl 2: S410-4. 93. Windegger TM, Nghiem S, Nguyen KH, Fung YL, Scuffham PA. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency. Vox Sang 2019; 114(3): 237-46. 94. Derman BA, Schlei Z, Parsad S, Mullane K, Knoebel RW. Changes in Intravenous Immunoglobulin Usage for Hypogammaglobulinemia After Implementation of a Stewardship Program. JCO oncology practice 2021; 17(3): e445-e53. 95. Edington HJ, Sutton KS, Bennett C, Chandrakasan S, Sterner-Allison J, Castellino SM. Dealing with a critical national shortage-Approaches to triaging immune globulin supply in pediatric hematology and oncology. Pediatr Blood Cancer 2020; 67(7): e28260. 96. Jones TR, Wilkie G. First steps into lean at the Australian red cross blood service. Vox Sanguinis 2016; Conference(Supplement 2): 14. 97. Tsapepas D, Der-Nigoghossian C, Patel K, Berger K, Vawdrey DK, Salmasian H. Medication stewardship using computerized clinical decision support: A case study on intravenous immunoglobulins. Pharmacology research & perspectives 2019; 7(5): e00508.
RkJQdWJsaXNoZXIy MTk4NDMw